Chinese Academy of Sciences

Shanghai Pharmaceuticals Holding Co., Ltd.

The Johns Hopkins University

Huazhong University of Science and Technology

China Unionpay Co., Ltd.

Shanghai Institute of Organic Chemistry, Chinese Acadmeny of Sciences

Biao Yu

Xin Cao

Jing Lu

Yue Ming Zhou

Gang Pei

Yuqian An

Shichao Huang

Fuchun Shi

Martin Gilbert Pomper

Jing Wang

Jun O Liu

Ning Wang

Il Minn

Danni Jiang

Min Guo

Junwei Chen

Qiaoling Wang

Pengfei Fang

Qingli He

The present invention relates to a novel therapeutic drug for a neurodegenerative disease and an application thereof. Provided is a novel compound of formula (I). The compound can effectively facilitate the proliferation of neural stem cells in both in vitro and in vivo experiments and can be used as a treatment approach for facilitating neuroregeneration to fight against cognitive decline associated with aging or a neurodegenerative disease.

Therapeutic drug for neurodegenerative disease and application thereof

The present invention relates to a novel compound for preventing or treating neurodegenerative diseases and use thereof. Provided is a novel compound of Formula (I). The compound can effectively promotes the proliferation of neural progenitor cells in both in vitro and in vivo experiments, and can serves as a treatment approach to promote nerve regeneration to fight against cognition impairment associated with aging and neurodegenerative diseases.

Compound for preventing or treating neurodegenerative disease and application thereof

Provided is the use of an aromatic ring drug in inhibiting a key transcription factor of malignant melanoma. In particular, provided is the use of a compound as represented by formula A, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition or preparation. The pharmaceutical composition or preparation is used for: (a) inhibiting a key transcriptional regulatory factor of malignant melanoma, namely MITF (Microphthalmia-associated Transcription Factor); (b) treating MITF-related diseases such as melanoma, pancreatic cancer, skin hypersensitivity and asthma; and (c) regulating physiological activities in which MITF is involved, such as skin whitening. In the formula, each group is as defined in the description.

Use of aromatic ring drug in inhibiting key transcription factor of malignant melanoma

Embodiments of the present disclosure relate to the field of computer technologies and, in particular, to an open-source-license analyzing method and apparatus, including: receiving a file-to-be-tested and a planning condition; detecting an open-source license involved in the file-to-be-tested; matching the detected open-source license with the planning condition to determine a first conflict between the detected open-source license and the planning condition; and generating a first risk assessment report based on the first conflict. The embodiments of the present disclosure are used to analyze and evaluate the risk of using open-source licenses.

Open-source-license analyzing method and apparatus

Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.

Glucose conjugates of triptolide, analogs and uses thereof

Disclosed are a retinoid compound, a preparation method therefor, intermediates thereof and an application thereof. The retinoid compound I of the present invention has a good tumor growth inhibition rate.

Retinoid compound, preparation method therefor, intermediates thereof and application thereof

Growing community of inventors

Shanghai, China

Biao Yu